Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion type Assertion NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_head.
- NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_provenance.
- NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion evidence source_evidence_literature NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_provenance.
- NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion SIO_000772 19891708 NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_provenance.
- NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion wasDerivedFrom befree-20150227 NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_provenance.
- NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_assertion wasGeneratedBy ECO_0000203 NP680527.RAdI6q8SZPptkePsTJSf-gIgLll6eU29hIifIOyvFSoFA130_provenance.